Mizuho Securities Remains a Buy on Aerie Pharma (AERI)

In a report issued on September 12, Difei Yang from Mizuho Securities maintained a Buy rating on Aerie Pharma (AERI), with a price target of $27.00. The company’s shares closed last Monday at $11.12, close to its 52-week low of $10.22.

According to TipRanks.com, Yang ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.7% and a 33.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Revance Therapeutics.

Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $27.50, which is a 158.7% upside from current levels. In a report issued on September 8, Guggenheim also initiated coverage with a Buy rating on the stock with a $20.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $26.26 and a one-year low of $10.22. Currently, Aerie Pharma has an average volume of 708K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts